Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with ...

AstraZeneca Plc’s breast cancer pill failed to delay disease progression more than the standard treatment in a late-stage trial, results that could dampen optimism around the medicine. Camizestrant ...

AstraZeneca Plc’s breast cancer pill was approved by the US Food and Drug Administration, a win for the drugmaker following an earlier vote against the medicine by the agency’s advisory panel. The ...

“We believe we’ve identified the right dose that allows us to get the right benefit within heart failure,” Mina Makar, SVP of global cardiovascular, renal and metabolism at AstraZeneca, told Fierce.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has suffered its second pipeline setback in little over a month after halting a late-stage lung cancer trial, even as shares in the drugmaker rose on Monday. The ...

AstraZeneca’s board scrapped merger talks with Bristol Myers Squibb on Aug. 3, days after reports emerged that the companies were discussing a roughly $400 billion tie-up, according to an Aug. 11 ...

AstraZeneca (AZN) had discussions with Bristol-Myers Squibb (BMY) through the spring and summer about a potential deal. The two companies were close to an agreement on price, and talks were taking ...

Few big-pharma bosses enjoy a stronger reputation on Wall Street than AstraZeneca’s AZN0.67%increase; up pointing triangle chief executive, Pascal Soriot. So the idea that he would stake his company’s ...

Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb's U.S.-centric business, but at the cost of slower growth and ...

AstraZeneca AZN-1.98%decrease; down pointing triangle shares fell sharply and Bristol Myers Squibb’s BMY-1.35%decrease; down pointing triangle climbed, after media reports that the two drugmakers held ...

UK drugmaker AstraZeneca has been exploring a deal to combine with US rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter. The deal could create ...